Sio Capital Management, LLC Ardelyx, Inc. Transaction History

Sio Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.51 - $1.17 $353,102 - $810,057	692,357 New	692,357 $408,000
Q1 2022 May 16, 2022	SELL	$0.65 - $1.18 $646,492 - $1.17 Million	-994,604 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$0.86 - $1.7 $363,368 - $718,287	422,522 Added 73.86%	994,604 $1.09 Million
Q3 2021 Nov 15, 2021	BUY	$1.27 - $8.17 $58,529 - $376,522	46,086 Added 8.76%	572,082 $755,000
Q2 2021 Aug 16, 2021	SELL	$6.55 - $8.98 $1.27 Million - $1.75 Million	-194,625 Reduced 27.01%	525,996 $3.99 Million
Q1 2021 May 14, 2021	BUY	$6.1 - $7.69 $190,930 - $240,697	31,300 Added 4.54%	720,621 $4.77 Million
Q4 2020 Feb 16, 2021	SELL	$5.05 - $7.1 $328,250 - $461,500	-65,000 Reduced 8.62%	689,321 $4.46 Million
Q3 2020 Nov 16, 2020	BUY	$5.25 - $7.08 $802,131 - $1.08 Million	152,787 Added 25.4%	754,321 $3.96 Million
Q2 2020 Aug 14, 2020	SELL	$5.37 - $8.11 $107,400 - $162,200	-20,000 Reduced 3.22%	601,534 $4.16 Million
Q4 2019 Feb 14, 2020	BUY	$4.23 - $8.29 $2.63 Million - $5.15 Million	621,534 New	621,534 $4.67 Million

219

141M

1.08M

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $815M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

Get notified when there are updates to the investment portfolio of Sio Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sio Capital Management, LLC with notifications on news.